Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384512 | 1.00 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AHIF1ASRC | |
| SCHEMBL2383429 | 0.91 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AHIF1AEGLN1 | |
| SCHEMBL2383427 | 0.91 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AHIF1AEGLN1 | |
| SCHEMBL12254454 | 0.91 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AHIF1ASRC | |
| SCHEMBL2384084 | 0.89 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2AHIF1ASRC | |
| SCHEMBL2384080 | 0.89 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2AHIF1ASRC | |
| SCHEMBL2385340 | 0.87 | L3MBTL1 (0.55) | L3MBTL1MEN1KMT2AHIF1ANLRP3 | |
| SCHEMBL2385339 | 0.87 | L3MBTL1 (0.55) | L3MBTL1MEN1KMT2AHIF1ANLRP3 | |
| SCHEMBL2385208 | 0.86 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AHIF1ANLRP3 | |
| SCHEMBL15419106 | 0.86 | GSK3B (0.56) | L3MBTL1MEN1KMT2AHIF1ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960363-B1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF | AMGEN INC (US) | 2014-01-22 | — | — | EP | claimed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4035/4885MEN1 3474/4885KMT2A 942/4885 |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4024/4885MEN1 3364/4885KMT2A 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.